Drawing for DFDA

USPTO serial 88564669

DFDA

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
EUBANK, REBECCA A
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with DFDA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Francis John Ciaramella, Esquire

Francis John Ciaramella, Esquire Francis John Ciaramella, PLLC110 Front Street, Suite 300Jupiter, FL 33477UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
042Dosage formulation development and analysis services, namely, pharmaceutical drug development services, testing services for pharmaceuticals, pharmaceutical products development, laboratory research services relating to pharmaceuticals, and testing, inspection or research of pharmaceuticals; Dosage formulation in the nature of pharmaceutical drug development services, pharmaceutical products development using Multi-Factor-At-a-Time strategies; Dosage formulation and analysis in the nature of pharmaceutical drug development services, pharmaceutical products development, and testing services for pharmaceuticals, namely, developing different dose and delivery systems in the nature of oral solids in the nature of tablets, capsules, gummies, candy, pastes, powder blends, oral semi-solids in the nature of soft-gels, gels in the nature of oral liquids, tincture, syrup, sprays, sublingual sprays, and oral care liquids, vitamins, mineral drinks, and topical formulations in the nature of dermal and transdermal creams, gels, lotions, and serums; Scientific research services in the nature of qualitative and quantitative analysis of key active compounds in pharmaceuticals, nutraceutical, cosmeceutical and therapeutic food products; Pharmaceutical research services in the nature of dosage and dose analysis in pharmaceuticals, nutraceutical, cosmeceutical and therapeutic food products to identify potency and strength of dosage; Scientific research services in the nature of forced degradation analysis of pharmaceuticals, nutraceutical, cosmeceutical and therapeutic food products to identify stability indication of the dosage and the shelf life determinationACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Oct 3, 2022MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Oct 3, 2022ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Mar 1, 2022NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jan 4, 2022NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 4, 2022PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 15, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 30, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 30, 2021XAECEXAMINER'S AMENDMENT ENTERED—
Nov 30, 2021GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Nov 30, 2021GNEAEXAMINERS AMENDMENT E-MAILED—
Nov 30, 2021CNEAEXAMINERS AMENDMENT -WRITTEN—
Nov 6, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 5, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 5, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 7, 2021GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 7, 2021GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 7, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 22, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 22, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 20, 2021ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Oct 21, 2020GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Oct 21, 2020GNSIINQUIRY TO SUSPENSION E-MAILED—
Oct 21, 2020CNSISUSPENSION INQUIRY WRITTEN—
Apr 21, 2020GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Apr 21, 2020GNSLLETTER OF SUSPENSION E-MAILED—
Apr 21, 2020CNSLSUSPENSION LETTER WRITTEN—
Apr 17, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 17, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 9, 2020ALIEASSIGNED TO LIE—
Apr 2, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 2, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 2, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 2, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 27, 2019DOCKASSIGNED TO EXAMINER—
Aug 21, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—

Frequently asked questions

Related guidance